Schrodinger, Inc. (SDGR) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Schrodinger, Inc. operates a physics-based computational platform for drug discovery and materials science, generating revenue through software licensing and drug discovery collaborations. The company maintains two reportable segments: Software and Drug Discovery.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $35,290 | $42,569 | $119,222 | $142,540 |
| Net Loss | $(38,136) | $(62,024) | $(146,907) | $71,390 |
| Diluted EPS | $(0.52) | $(0.86) | $(2.02) | $0.95 |
| Operating Cash Flow (9M) | $(126,255) | $(99,478) | — | — |
| Cash & Equivalents (Sep 30, 2024) | $160,416 | — | — | — |
| Total Liquidity (Cash + Securities) | $388,679 | — | — | — |
Note: Total Liquidity includes Cash, Cash Equivalents, Restricted Cash, and Marketable Securities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 17% year-over-year in Q3 2024. This was driven primarily by a 75% drop in Drug Discovery revenue ($3.4M vs. $13.7M), attributed to the timing of milestone recognitions and the discontinuation of certain collaboration programs by partners (e.g., BMS). Software revenue grew 10% to $31.9M, with Hosted Software revenue increasing 61%.
- Improved Net Loss: Net loss narrowed to $38.1M in Q3 2024 from $62.0M in Q3 2023. The prior year's loss was partially offset by significant non-cash fair value gains on equity investments (Structure Therapeutics and Morphic) and a realized gain on the Nimbus investment in 2023, which were absent or reduced in 2024.
- Operating Expenses: Total operating expenses increased 8% to $86.2M in Q3 2024, with Research and Development (R&D) rising 9% due to continued investment in proprietary drug programs (SGR-1505, SGR-2921, SGR-3515).
- Equity Investments: The company disposed of its equity stake in Morphic Holding, Inc. in August 2024 for approximately $47.6M. The company recognized a $25.5M unrealized gain on equity investments in Q3 2024.
Guidance, Outlook, and Risks
- New Collaboration: On November 11, 2024 (subsequent to period end), Schrodinger entered into a collaboration with Novartis Pharma AG. The deal includes a $150M upfront payment and up to $2.272B in potential milestones.
- Drug Pipeline Progress: The company is advancing three proprietary programs: SGR-1505 (MALT1 inhibitor, Phase 1), SGR-2921 (CDC7 inhibitor, Phase 1, Fast Track designation), and SGR-3515 (WEE1/MYT1 inhibitor, Phase 1). Initial data for these trials is expected in 2025.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($398.4M as of Sep 30, 2024) are sufficient to fund operations for at least the next 24 months.
- Risks: Key risks include the company's history of significant operating losses, dependence on collaboration milestones for revenue, the uncertainty of clinical trial outcomes, and the potential need for additional capital if revenue growth does not accelerate.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of the 75% decline in Drug Discovery revenue and the extent to which the new Novartis deal will offset this in future quarters.
- Cash Burn Rate: Monitor the $126.3M cash used in operating activities over the last nine months against the $398.4M liquidity position to assess runway.
- Equity Investment Volatility: Note that net income/loss is heavily influenced by non-cash fair value adjustments of equity stakes (e.g., Structure Therapeutics); verify the core operating loss excluding these items.
- Clinical Milestones: Track the progress of the three proprietary Phase 1 trials (SGR-1505, SGR-2921, SGR-3515) as they represent the primary path to future proprietary revenue.
- ATM Facility: Confirm the remaining capacity of the At-The-Market (ATM) offering program ($241.1M remaining) as a potential source of near-term capital.